Harvard Bioscience Inc (HBIO) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access HBIO Annual Balance Sheets →
The balance sheet data below highlights changes in Harvard Bioscience Inc's financial position over recent quarters.
Quarterly Report, GAAP in USD millions
ITEM
(Jun 30 2026)
(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Assets
Cash & cash equivalent6.50
Cash & Short-term Investments6.00
Accounts receivable14.50
Inventories22.23
Other Current Assets3.23
Total Current Assets46.46
Equipment/Property/Plant Net5.35
Goodwill net9.33
Intangible Assets6.22
Other Assets, Noncurrent8.93
Operating Lease Right Of Use Asset6.73
Total Assets76.29
Liabilities
Accounts Payable, Current AC6.22
Accrued Liabilities, Current AC2.17
Secured Debt, Current LO0.00
Other Liabilities, Current16.40
Total Current Liabilities24.79
Long-term debt36.68
Total Long-term Debt36.68
Other liabilities, Noncurrent7.39
Contract With Customer Liability Current3.67
Operating Lease Liability Noncurrent6.36
Total Liabilities68.87
Stockholders' Equity
Common Stock Value0.45
Additional Paid In Capital Common Stock240.39
Retained Earnings / Accumulated Deficit-221.04
Accumulated Other Comprehensive Income-12.38
Other Equity-12.38
Common Stockholder's Equity7.42
Total Stockholder's Equity7.42
Liabilities & Stockholder's Equity76.29
4 historic quarters locked

Sign in to unlock the full Harvard Bioscience Inc balance sheet history.

About Harvard Bioscience Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-Q filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001171843-26-005425

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.